Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - Allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of the quarterly dividend payout by over 70% [4]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price drop of more than 27% [5]. Group 2: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Group 3: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for securing substantial monetary relief for investors in securities fraud cases [7].

Core Viewpoint - The article discusses a class action lawsuit against DoubleVerify Holdings, Inc. for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and failure to disclose critical business challenges during the class period from November 10, 2023, to February 27, 2025 [1][3]. Company Allegations - The lawsuit alleges that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, where DoubleVerify's capabilities were limited, impacting its competitive position [3]. - It is claimed that the development of technology for closed platforms was more expensive and time-consuming than disclosed, limiting DoubleVerify's ability to monetize its Activation Services [3]. - Competitors were reportedly better positioned to incorporate AI into their offerings, adversely affecting DoubleVerify's profits [3]. - The company allegedly overbilled customers for ad impressions served to declared bots, and its risk disclosures were misleading [3]. Financial Impact - On February 28, 2024, DoubleVerify issued lower revenue growth expectations for Q1 2024, leading to a stock price drop of over 21% [4]. - On May 7, 2024, the company cut its full-year 2024 revenue outlook due to reduced ad spending, resulting in a nearly 39% decline in stock price [5]. - On February 27, 2025, DoubleVerify reported lower-than-expected Q4 2024 sales and earnings, with a stock price drop of more than 36% following the announcement [6]. Legal Process - Investors who purchased DoubleVerify common stock during the class period can seek appointment as lead plaintiff in the lawsuit, representing the interests of the class [7]. - The lead plaintiff can select a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [7]. About the Law Firm - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [8]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [8].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - Allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of the quarterly dividend payout by over 70% [4]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price drop of more than 27% [5]. Group 2: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Group 3: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 [7].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were countered by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - Following the acquisition of Dermavant Sciences Ltd., Organon reportedly prioritized debt reduction over dividend payouts [4]. Financial Impact - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, which led to a stock price drop of over 27% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record, including the largest securities class action recovery in history at $7.2 billion in the Enron case [7].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were countered by a new debt reduction strategy that resulted in a more than 70% decrease in the quarterly dividend [4]. - Following the acquisition of Dermavant Sciences Ltd., Organon reportedly prioritized debt reduction over dividend payouts [4]. Financial Impact - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, which led to a stock price decline of over 27% [5].

Core Viewpoint - The DoubleVerify Holdings, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misleading statements and undisclosed risks impacting the company's stock performance during the specified class period [1][3]. Company Allegations - The lawsuit claims that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, where the company's technological capabilities were limited, affecting its competitive position [3]. - It is alleged that the development of technology for closed platforms was more expensive and time-consuming than disclosed, limiting DoubleVerify's ability to monetize its Activation Services [3]. - Competitors were reportedly better positioned to incorporate AI into their offerings, which negatively impacted DoubleVerify's profits and competitive edge [3]. - The company is accused of systematically overbilling customers for ad impressions served to bots, and its risk disclosures were misleading, presenting adverse facts as mere possibilities [3]. Stock Performance Impact - Following a lower revenue growth expectation announcement on February 28, 2024, DoubleVerify's stock price fell over 21% [4]. - On May 7, 2024, after cutting its full-year 2024 revenue outlook due to reduced customer ad spending, the stock price dropped nearly 39% [5]. - A report on February 27, 2025, detailing lower-than-expected sales and earnings due to reduced customer spending led to a further stock price decline of more than 36% [6]. Legal Process - Investors who purchased DoubleVerify common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [7].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were offset by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - The lawsuit also states that Organon intended to prioritize debt reduction following its acquisition of Dermavant Sciences Ltd [4]. Financial Impact - On May 1, 2025, Organon reported first quarter 2025 financial results, announcing a reduction in its dividend payout from $0.28 to $0.02, which led to a stock price decline of over 27% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Bakkt Holdings, Inc. related to misrepresentation of the company's financial stability and revenue sources [1][2]. Group 1: Allegations and Misrepresentation - Insiders at Bakkt allegedly caused the company to misrepresent or fail to disclose critical information regarding the stability and diversity of its crypto services revenue [2]. - It was revealed that Bakkt's crypto services revenue was heavily reliant on a single contract with Webull, raising concerns about revenue sustainability [2]. - The company's ability to maintain key client relationships was also questioned, suggesting that previous positive statements about Bakkt's business and prospects were misleading [2]. Group 2: Shareholder Actions - Shareholders who purchased BKKT shares prior to March 25, 2024, are encouraged to contact Kuehn Law to discuss potential legal actions, as there may be limited time to enforce their rights [3]. - Kuehn Law offers to cover all case costs and does not charge its investor clients, emphasizing the importance of shareholder involvement in maintaining market integrity [4].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were countered by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - Following the acquisition of Dermavant Sciences Ltd., Organon prioritized debt reduction, which was not disclosed to investors [4]. Financial Impact - On May 1, 2025, Organon reported its first quarter 2025 financial results, announcing a drastic reduction in its dividend payout from $0.28 to $0.02, which led to a more than 27% drop in the stock price [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”), have until Monday, July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutic ...